Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79